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p38g MAPK contributes to left ventricular remodeling
after pathologic stress and disinhibits calpain through
phosphorylation of calpastatin
Aminah A. Loonat,* E. Denise Martin,* Negin Sarafraz-Shekary,* Katharina Tilgner,* Nicholas T. Hertz,†
Rebecca Levin,† Kevan M. Shokat,† Alma L. Burlingame,† Pelin Arabacilar,* Shahzan Uddin,* Max Thomas,*
Michael S. Marber,* and James E. Clark*,1
*School of Cardiovascular Medicine and Science, British Heart Foundation (BHF) Centre, King’s College London, London, United Kingdom;
and †University of California–San Francisco, San Francisco, California, USA
ABSTRACT:Despite the high andpreferential expression of p38gMAPK in themyocardium, little is known about its
function in the heart. The aimof the current studywas to elucidate the physiologic andbiochemical roles of p38g in
the heart. Expression and subcellular localization of p38 isoformswasdetermined inmouse hearts. Comparisons of
the cardiac function and structure ofwild-type and p38g knockout (KO)mice at baseline and after abdominal aortic
banding demonstrated that KOmice developed less ventricular hypertrophy and that contractile function is better
preserved. To identify potential substrates of p38g, we generated an analog-sensitive mutant to affinity tag en-
dogenous myocardial proteins. Among other proteins, this technique identified calpastatin as a direct p38g sub-
strate. Moreover, phosphorylation of calpastatin by p38g impaired its ability to inhibit the protease, calpain. We
have identified p38g as an important determinant of the progression of pathologic cardiac hypertrophy after aortic
banding inmice. In addition,wehave identified calpastatin, among other substrates, as a novel direct target of p38g
thatmay contribute to the protection observed in p38gKOmice.—Loonat, A.A.,Martin, E.D., Sarafraz-Shekary,N.,
Tilgner, K., Hertz, N. T., Levin, R., Shokat, K.M., Burlingame, A. L., Arabacilar, P., Uddin, S., Thomas,M., Marber,
M. S., Clark, J. E. p38g MAPK contributes to left ventricular remodeling after pathologic stress and disinhibits
calpain through phosphorylation of calpastatin. FASEB J. 33, 13131–13144 (2019). www.fasebj.org
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The current study provides experimental evidence for a
putative role for p38gMAPK in the progression of cardiac
hypertrophyandheart failure andelucidates amechanism
of action. By using an in vivomouse model of cardiac hy-
pertrophy, this study demonstrates how ablation of p38g
MAPKexpression ameliorates cardiac function after aortic
constriction. By using a modified analog-sensitive kinase
in vitro and subsequent proteomic analysis, we identify
putative substrates of p38g MAPK and demonstrate the
functional consequence of substrate phosphorylation.
p38 MAPKs are stress-activated serine/threonine ki-
nases that sense a variety of cardiac pathologies (1). The
family consists of 4 isoforms—a, b, g, and d. Studies have
historically focused on the p38a and p38b isoforms as
they are ubiquitously expressed and inhibited by widely
available tools, including pyridynylimadazole inhibitors,
such as SB203580. The remaining 2 p38 MAPK isoforms
are not inhibited by pyridynylimadazoles and exhibit
differential expression patterns (2). For example, p38g is
highly expressed in skeletal and cardiacmuscle, and p38d
is highly expressed in endocrine glands (3).
Whereas all 4 isoforms are expressed in the heart, p38a
and p38g have been shown to be the 2 most abundantly
expressed isoforms, with comparable myocardial protein
content (3). There are extensive studies that have docu-
mented the role of p38a in various cardiac disease states,
especially in response to ischemia and infarction (1);
however, little has been reported about the functional role
of p38g in the heart. Given the differential localization of
p38a and p38g in unstimulated cardiomyocytes and in
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hearts of mice subjected to pressure overload (3, 4), it is
unlikely that p38g is functionally redundant.
The lack of tool compounds has also impeded the
identification of p38g substrates. The PDZ domain-
interacting motif—exclusive to p38g among the MAPK
family—has aided in the search for specific substrates (5).
The short amino acid sequence, KETAL, in the C-terminal
of p38g can directly dock to PDZ domains of proteins and
therefore adds a unique dimension to p38g signaling. Ex-
amples of proteins that have been found to interact with
p38g via their PDZdomains and undergo phosphorylation
area1-syntrophin (5),PSD-95 (6), SAP97(7),PTPH1(8), and
DEPTOR (9); however, there are likely to be cardiac sub-
strates of p38g that are not PDZ dependent. One technique
to identify such substrates is an in vitro chemical genetic
approach firstdescribedbyShokat andcolleagues (10).This
technique was initially developed to identify substrates of
v-Src tyrosine kinase. The approach requires the generation
of an analog-sensitive (AS) kinase that can utilize bulky,
orthogonal N6 expanded ATP analogs that cannot be used
bywild-type (WT)kinases.TheATPanalog isalsomodified
at theg-phosphate to substitute a thiol group in place of the
hydroxyl group (11). As such, substrate proteins undergo
thiophosphorylation, which allows substrates of the kinase
of interest to be specifically tracked and identified from a
complex mixture of proteins, such as cell or tissue extracts.
The aim of the current study was to examine the role
that p38g plays cardiac hypertrophy by using gene-
targeted mouse lines and to identify its potential myo-
cardial substrates via a Shokat approach.
MATERIALS AND METHODS
Mice colonies
All animal experimentswere carried out in accordancewithHome
Office regulations as detailed in the Home Office Guidance on the
Operation of Animals (Scientific Procedures) Act 1986 HMSO
(London), which mirrors those of the Guide for the Care and Use of
Laboratory Animals [National Institutes of Health (NIH), Bethesda,
MD, USA]). We used mice with targeted disruption of p38g and
p38d MAPK (p38gdKO), the generation of which has been de-
scribedbySabioetal. (7).Thesemicewerebackcrossedwithoutbred
C57/BL6 mice for at least 5 generations to develop p38g single
knockout (KO)mice (p38gKO).PCRprotocols forgenotyping these
mice have been described by Sabio et al. (7).
Abdominal aortic banding
Male mice (age 8–10 wk, 22–26 g) from p38gdKO or p38gKO colo-
nieswereused in all experiments.Micewere subjected to abdominal
aorticbandingasdescribedbyBoguslavskyietal. (12). Inbrief,asmall
metal tube (28 G) was tied against the supra-renal aorta to restrict
blood flow and provide increased afterload and a reproducible de-
crease in renal blood flow to induce cardiac hypertrophy. Bupre-
norphine (single-dose 20 mg/kg, i.p.; Vetergesic, Ceva Animal
Health Ltd., France) was used for perioperative analgesia. After in-
vasive pressure–volumemeasurements, euthanasia was performed
withanoverdoseof 300mg/kgpentobarbital (Pentoject).Deathwas
confirmed by monitoring cardiac activity and respiration. For im-
munohistochemistry, heart excision was performed after terminal
anesthesia by intraperitoneal injection of pentobarbital (300mg/kg)
and heparin (150 IU) and flushing of the heart using ice-cold saline.
After excision, hearts were coated in optimum cutting temperature
compound(TissueTek;Sakura,Torrance,CA,USA)andsnap-frozen
in abathof liquidnitrogen–cooled isopentane andattached to a cork
board before cryosectioning at 30 mm.
Echocardiography and left ventricle function
All mice received preoperative cardiac ultrasound, and serial
echocardiography was used to assess cardiac function after sur-
gery. Mice were anesthetized by using 2% isofluorane (100% ox-
ygen),maintainedon ahomeothermic platform, and examinedby
echocardiography using a high-resolution Vevo 770 echocardi-
ography system (VisualSonics, Toronto, ON, Canada) with an
RMV-707B transducer at 30MHz.High-resolutionparasternal left
ventricle (LV) long- and short-axis M-mode and B-mode images
were obtained for offline measurements with Vevo software
(VisualSonics) to calculate LV function and mass. At the end of
experiments, mice were subjected to invasive LV function assess-
mentbypressure–volumeanalysis asdescribedbyClark et al. (13).
Immunocytochemistry
Mouse cardiacmyocyteswere isolated as described byHaworth et al.
(14). Freshly isolated cardiac myocytes were cultured on laminin-
coatedculturedishesfor1hinDMEM(MilliporeSigma,St.Louis,MO,
USA). Media were removed and cells were washed with PBS and
fixed by 4% paraformaldehyde in PBS for 15min. This was followed
by three 5-minwasheswith PBS. Cells were next permeabilizedwith
0.2% Triton X-100 in PBS, followed by a 5-min wash with PBS and
blocking with 100 ml/dish of 5% normal goat serum. Specific Abs
against pan-isoform p38 (9212; Cell Signaling Technology, Danvers,
MA,USA), p38b (P38-11A5; ThermoFisher Scientific,Waltham,MA,
USA), p38g (AF1347; R&D Systems, Minneapolis, MN, USA), and
p38d (ab188324; Abcam, Cambridge, United Kingdom) were diluted
1:100 in addition to either primarymouse a-actinin (diluted 1:500) or
primaryrabbita-actinin(diluted1:200) inbuffer thatcontained20mM
Tris base,155mMNaCl, 2mMEGTA, 2mMMgCl2, pH 7.5, and 1%
bovineserumalbumin.Disheswereplacedintoahumidchamberand
incubated overnight at 4°C. The next day, cells were washed in PBS
and incubated overnight at 4°C with secondary Abs: donkey anti-
mouse Cy3 (diluted 1:500; 715-165-150; Jackson ImmunoResearch
Labs,WestGrove, PA,USA), goat anti-rabbitAlexaFluor 647 (diluted
1:100; 111-605-003; Jackson ImmunoResearch Labs), and DAPI (di-
luted 1:100; MilliporeSigma). Cells were then washed as before and
mounted with a droplet of mounting medium (0.1 M Tris, 35 ml
glycerol,and2.5gn-propylgallate)andcoveredwith30-mm-diameter
glass coverslips (Science Warehouse, Leeds, United Kingdom). The
verticalsidesofeachdishwereremovedwithahotwireandcoverslips
were sealed with nail varnish. Each dish was then glued onto a mi-
croscope slide and kept at 4°C until analysis by confocal microscopy.
Immunohistochemistry
After being cryosectioned and mounted onto poly-lysine slides
(Polysine; VWR, Radnor, PA, USA), tissue sections were air dried
andbriefly fixedwith100%acetone for 15minat roomtemperature.
Heart sections were circled with wax pen (Dako, Carpinteria, CA,
USA), then incubatedwith PBS that contained 0.1% (v/v) Triton X-
100 and 1% (w/v) bovine serumalbumin for 20min. Sampleswere
incubated overnight at 4°C with specific primary Abs against
b-myosin heavy chain (b-MHC; diluted 1:200 in b-PBS; Milli-
poreSigma). The next day, samples were washed with PBS and
incubated for an additional 2 hwith secondaryAb (diluted 1:200 in
PBS and Cy3-conjugated donkey anti-mouse IgG; 715-165-150;
Jackson ImmunoResearch Labs) and Alexa Fluor 488–conjugated
wheat germ agglutinin (Thermo Fisher Scientific). Slides were
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washed and coverslips were placed with mounting medium that
contained DAPI (Dako) before being visualized at the appropriate
wavelengths by using a Leica SP-5 confocal microscope (Leica
Microsystems, Wetzlar, Germany). A total of 5 images from each
heart sectionwere used to quantifymyocyte cross-sectional area by
using a custommacro in ImageJ (v1.50i;NIH),with at least 250 cells
being measured for each heart. b-MHCwas scored independently
as positive (red) cells per high-powered field.
Cloning and purification of recombinant
p38g proteins
The clone of the open reading frameofmurinemapk12 (p38g)was a
kind gift from the Rudnicki Laboratory (University of Ottawa, Ot-
tawa, ON, Canada) (15). The full-length insert was subcloned into
pETDuet-1 (Thermo Fisher Scientific) 39 to a 63 His coding se-
quence. Insertion of cDNA into pETDuet-1 was confirmed by elec-
trophoresis on agarose gels and sequencing. For generating C9
truncated p38g and AS p38g, mutations were introduced by using
the QuikChange II Site-Directed Mutagenesis Kit (Agilent Tech-
nologies, Santa Clara, CA, USA) according to the manufacturer’s
instructions.ForgeneratingASp38g, thegatekeepermethionine109
residue was mutated to a glycine and additional rescue
mutations—A160L and L170A—were introduced to prevent the
loss of kinase activity. Mutagenesis was confirmed by sequencing.
p38g constructs were transformed into the Escherichia coli–
competent strain, Rosetta BL21 (DE3; Bioline, Toronto, ON, Can-
ada).TransformedE.coliwere thenselectedonLBagarmediumthat
contained 100 mg/ml ampicillin. Transformed bacteria were in-
oculated in LB media that contained 100 mg/ml ampicillin and
grown to an optical density of 0.5 at 600 nm, then expression of 63
His protein was induced by the addition of 1 mM isopropyl-b-D-
thiogalactoside (IPTG) for 5 h at 21°C with constant shaking. p38g
proteins (63 His) were purified by immobilized metal affinity
chromatography using nickel-nitriloacetic acid agarose beads (Qia-
gen, Germantown, MD, USA) and a batch protocol as follows:
bacterialcellpelletswereresuspendedin ice-cold lysisbuffer (50mM
Tris, pH 7.4, 500mMNaCl, 2mMDTT, and 10mM imidazole that
contained a protease inhibitor cocktail; Roche, Basel, Switzerland).
Cell lysis was performed by using a high-intensity ultrasonic pro-
cessor. Lysates were clarified by centrifugation at 10,000 rpm for 30
min at 4°C. Supernatantswere filtered through 0.45-mMmembrane
filters before being incubated with lysis buffer–equilibrated nickel-
nitriloaceticacidagarosebeadsfor1hat4°Conarotator.Beadswere
pelleted by centrifugation at 3000 rpm for 5 min at 4°C and the
supernatant was discarded. Beads were subsequently washed 6
timeswith 15ml ice-coldwash buffer (50mMTris, pH7.4, 500mM
NaCl, 2 mM DTT, and 20 mM imidazole). p38g proteins (63His)
were eluted by increasing the imidazole concentration stepwise
from 0.05 to 0.5 M. p38g 63 His peak fractions were pooled and
dialyzedovernightat4°Cagainst 232Lofabuffer that consistedof
50mMTris,pH7.4, 100mMNaCl,and2mMDTT.Thepurityof63
His p38g proteins was further refined by ion exchange chromatog-
raphy on aMonoQ5/10 column (GEHealthcare Lifesciences, Little
Chalfont, United Kingdom) equilibrated in 50 mM Tris, pH 7.4,
100mMNaCl,and2mMDTT.p38gproteinwaselutedbyapplying
40 columnvolumesof a linear 0.1–0.6MNaClgradient. p38g eluted
at ;190 mM NaCl. All chromatographic steps were performed at
4°C. Fractions from each chromatographic step were analyzed by
SDS-PAGE and/or Western blot analysis. Fractions that contained
highly purified p38g protein were pooled and used for subsequent
biochemical studies. Protein concentration was determined by
Pierce Bradford assay (Thermo Fisher Scientific).
Activation of nonactive p38g proteins
Purified nonactive 63His p38g proteins (0.2 mg/ml) were acti-
vated by incubation with constitutively active MBP–MAPK
kinase6 (0.02mg/ml) in thepresenceof0.1mMATPand13kinase
buffer (50 mM Tris, pH 7.5, 10 mMMgAc, 0.1 mM EGTA, 0.1% 2-
ME) for 1.5 h at 30°C without mixing. To separate MAPK kinase
6 from p38g proteins, kinase reactions were incubated with amy-
lose resin for 30min at 4°C. Resinwas pelleted by centrifugation at
3000 rpm for 5 min at 4°C, and the supernatant that contained
activated protein was collected and analyzed for phosphorylation
by SDS-PAGE, Phostag SDS-PAGE, and Western blot analysis.
Activated proteins were dialyzed into storage buffer (50 mM
Tris, pH 7.5, 0.1 mMEGTA, 270 mM sucrose, 150 mMNaCl, 0.1%
2-ME, 0.2 mM PMSF, and 1 mM benzamidine) overnight at 4°C.
HEK cell transfection
HEK293 cells were transfected at 70% confluency in Opti-
MEM I (Thermo Fisher Scientific) by using Turbofect (Thermo
Fisher Scientific) withWTor canonicallymutated TAB1 (V408A,
M409A; 1-418B; CM) TAB1 plasmid DNA as described by
DeNicola et al. (16).
Cloning and purification of recombinant
LDB3 protein
His-LDB3 was generated by subcloning the open reading frame
of murine ldb3 from the pcR4-TOPO vector (Source Bioscience,
Nottingham, United Kingdom) into the pETDuet-1 (Thermo
Fisher Scientific) expression vector (Novagen, London, United
Kingdom). SubsequentLDB3cloningandpurification stepswere
as described above for the generation of recombinant p38g pro-
teins with the following modification: bacteria were cultured at
26°C after IPTG induction.
Cloning and purification of recombinant
calpastatin proteins
RNA was extracted from WT mouse heart stored in RNAlater
(Thermo Fisher Scientific) by using an RNeasy Fibrous Tissue Kit
(Qiagen) according to the manufacturer’s instructions. cDNA was
generated by using Superscript III Reverse Transcriptase (Thermo
Fisher Scientific) according to the manufacturer’s instructions. The
resulting RNA/cDNA hybrids were used as templates to generate
double-stranded calpastatin DNA using Platinum Pfx DNA poly-
merase (Thermo Fisher Scientific) according to the manufacturer’s
instructions. The full-length insertwas subcloned into pGEX-3X (GE
Healthcare Lifesciences) 39 to a GST coding sequence. Insertion of
cDNA into pGEX-3X was confirmed by electrophoresis on agarose
gels and sequencing. To generate calpastatin mutants, mutations
were introduced by using the QuikChange II Site-Directed Muta-
genesis Kit according to the manufacturer’s instructions. Mutagen-
esiswasconfirmedbysequencing.Transformationandexpressionof
WTandmutant calpastatin constructs intoE. coliwere carried out as
described for p38gwith the following variations: 0.1mM IPTGwas
used to induce the expression of calpastatin proteins; and bacterial
cells were grown at 37°C after induction. GST-calpastatin proteins
were purified by glutathione sepharose chromatography.
Bacterial cells were resuspended in ice-cold lysis buffer (PBS,
pH 7.4, 2 mM DTT, and protease inhibitor cocktail; Roche). Cell
lysis was performed by using a high-intensity ultrasonic pro-
cessor. Lysates were clarified by centrifugation at 4600 rpm for
40 min at 4°C. Supernatant was filtered through a 0.45-mmmem-
brane filter before being incubated with lysis buffer–equilibrated
glutathione sepharose beads (GE Healthcare Lifesciences) for 1 h
at 4°C on a rotator. Beads were pelleted by centrifugation at 3000
rpm for 1 min at 4°C and the supernatant was discarded. Beads
were subsequently washed with 10 ml ice-cold PBS for 2 min at
room temperature on a rotator. We carried out 5 additional 10-ml
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washes.GST-calpastatinwaselutedbyapplying1.5-mlvolumesof
a 10–40 mM reduced glutathione gradient. Fractions that con-
tainedGST-calpastatinwerepooled anddialyzedovernight at 4°C
against 232Lof buffer that contained 50mMTris, pH8.0, 50mM
NaCl, 2 mMDTT.
In vitro kinase assays
Phosphorylation of substrates was performed in vitro in kinase
buffer (25 mM Tris, pH 7.5, 5 mM b-glycerophosphate, 2 mM
DTT, 0.2mMNa3VO4, and 10mMMgCl2) and contained 200 ng
of active p38g, 1 mM ATP, ATP-g-S or 6-PhEt-ATPgS (BioLog,
Minden, Germany), and 1 mg of recombinant ATF2 (Cell Sig-
naling Technology), a1-syntrophin (Creative Biomart, Shirley,
NY, USA), LDB3, or calpastatin substrate. Reactions were in-
cubated at 30°C for 30 min. Reactions were stopped by adding
23 Laemmli sample buffer and boiling at 100°C for 5 min. To
detect thiophosphorylated substrates, kinase reactions were
stopped with 20 mM EDTA and alkylated with 5 mM p-
nitrobenzylmesylate (PNBM;Abcam)orvehicle for1–2hat room
temperature before the addition of 23 Laemmli sample buffer.
Thiophosphorylation of p38g substrates
in heart homogenate
Kinase reactions (220ml)wereperformedasabovebut contained2
mgof heart homogenate, 20mgof active p38g, 1mMPhe-Eth-g-S,
0.4 mM ATP, and 3 mM GTP. Reactions were incubated at 30°C
for 1 h and stopped with 20 mM EDTA. A 10-ml sample of each
reaction was removed for alkylation with 5 mM PNBM to check
the reaction byWestern blot analysis using an anti-thiophosphate
ester Ab. Samples were frozen in liquid N2 and stored at 280°C
until the covalent capture procedure was performed.
Immunoblot analysis
Samples were resolved on a 10% reducing SDS polyacrylamide
gel and blotted onto a PVDF membrane. Membranes were
blocked for 1 h in 1.33% low-fat milk and 0.33% bovine serum
albumin in Tris-buffered saline (pH 7.4) and 0.1% Tween-20.
PrimaryAbswere incubatedovernightat 4°Cwithagitation.Abs
used included anti–dual-phosphorylated p38 (Thr180 and
Tyr182; 4511; Cell Signaling Technology), anti-p38a (1:2000;
MA5-15116; Thermo Fisher Scientific), anti-p38b (1:1000; P38-
11A5; Thermo Fisher Scientific), anti-p38d (1:2000; ab188324;
Abcam), anti-p38g (1:8000; AF1347; R&D Systems), anti-
phosphorylated ATF2 (1:5000; 9221; Cell Signaling Technol-
ogy), anti-ATF2 (1:4000; 9226; Cell Signaling Technology),
anti–thiophosphate ester (1:8000; ab92570; Abcam), anti-
PDLIM5 (H00010611-A02; Abnova, Taipei, Taiwan), anti–
a1-syntrophin (ab11187; Abcam), anti-calpastatin (1:2000;
4146;Cell SignalingTechnology), customanti–dual-phosphorylated
calpastatin (T197/S200), and anti-phosphorylated calpastatin (1:
1000; T448; Cambridge Research Biochemicals, Billingham, United
Kingdom). After washing and incubating with the appropriate
horseradish peroxidase–conjugated secondary Ab (GE Healthcare
Lifesciences), Ab–antigen complexes were visualized by ECL
(Pierce, Rockford, IL, USA).
Estimation of p38 MAPK isoform expression
Whole-heart homogenates were spiked with GST-tagged recombi-
nant proteins (240 ng/well) (Cell Signaling Biotechnology) and
probedwith isoform-specific mAbs and a total (pan-isoform) Ab as
described above. In this way, by using serially diluted recombinant
protein (0.4–246.0 mg/well), standard curves were generated for
each specific isoformAb, and the relative endogenous expression of
each isoform was determined by using GraphPad Prism (v6;
GraphPad Software, La Jolla, CA, USA).
Phostag SDS-PAGE and silver staining
For Phostag gel analysis of calpastatin phosphorylation, a Bis-Tris–
buffered neutral pH gel system was adopted. For this system,
samples were added to 23 lithium dodecyl sulfate loading buffer
(282 mM Tris base, 212 mM Tris HCl, pH 8.5, 20% glycerol,
4% lithium dodecyl sulfate, 200 mM DTT, 1 mM EDTA, 0.66 mM
SERVA Blue G250, and 0.35 mM Phenol Red) to give a 13 final
concentration. Samples were heated to 70°C for 10 min and centri-
fugedat 10,000 rpm for 2min. Sampleswere separatedbyhand-cast
8% Bis-Tris PAGE mini-gels that were supplemented with 50 mM
Phostag acrylamide and 100 mM Zn(NO3)2 with a 4% stacking
gel.Gelswereelectrophoresedat90Vvia thestackinggel for;20min
and 120 V via the resolving gel. After electrophoresis, gels were
stained with silver using a Modified PlusOne Staining Kit (GE
HealthcareLifesciences) according to themanufacturer’s instructions.
Covalent capture of thiophosphorylated peptides
Thiophosphorylated peptides were isolated and converted to
phosphopeptides for analysis by liquid chromatography–tandem
mass spectrometry (LC-MS/MS) as described by Dingar et al. (3).
LC-MS/MS and data analysis
Analysis of phosphopeptideswas carried out by the Bio-Organic
Biomedical Mass Spectrometry Resource at University of Cal-
ifornia, SanFrancisco (A.L.B.) byusingaLinearTrapQuadrupole
Orbitrap Velos electron transfer dissociation mass spectrometer
(Thermo Fisher Scientific). Peptides were first separated by
reverse-phase liquid chromatography using Eksigent nano 1D
HPLC (Eksigent, Dublin, CA, USA) that was equipped with a
75 mm 3 15 cm reverse-phase C-18 column (LC Packings; Con-
quer Scientific, San Diego, CA, USA). A 3–32% acetonitrile gra-
dient in 0.1% formic acid was applied (350 nl/min flow rate) to
separate peptides. LC-MS/MS was achieved by coupling the
reverse-phase column with an atmospheric pressure ionization
source in the mass spectrometer. Peptides were analyzed in pos-
itive ion mode. The 2 most intense multiple charged peaks from
each mass spectrometry spectrum were selected for subsequent
fragmentationwith both collision-induced dissociation (CID) and
electron transfer dissociation mechanisms to generate fragmen-
tation spectra.MS/MS spectrawere searched against theUniProt
databasebyusingProteinProspector software to identifyproteins
and phospho sites.
LC-MS/MS of calpastatin Phostag
Excised gel bands were washed in 100 mMNH4HCO3 for 5 min
before washing with acetonitrile for 5 min. Supernatant was
removed, and gel pieces were rehydrated with additional ace-
tonitrile. Acetonitrile was removed, and gel pieces were dehy-
drated by using a SpeedVac. Gel pieces were rehydrated by
incubatingwith 10mMDTTat 56°C for 30min. Supernatantwas
removedand25-minacetonitrilewasheswere repeatedasbefore
with subsequent gel dehydration by using a SpeedVac. Next,
55 mM iodoacetamide was added to the samples and incubated
at room temperature for 20 min in the dark. Supernatant was
discarded, and 2 5-min acetonitrile washes were carried out. For
complete destaining of gels, gel pieces were incubated in a 1:1
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solution of 100 mM NH4HCO3 and acetonitrile at 37°C for
30 min. Supernatant was removed, and 2 5-min acetonitrile
washes were carried out with subsequent gel dehydration by
using a SpeedVac. Sufficient volume of 13 ng/ml trypsin in
50mMNH4HCO3 to cover gel pieces was added to samples and
incubated at 4°C for 20 min. Unabsorbed trypsin was removed,
and gel pieces were incubated with aminimal volume of 50mM
NH4HCO3 to cover gel pieces. Samples were incubated at 37°C
for 2 h, then overnight at room temperature. Gel pieces were
washed with 50 mM NH4HCO3 at 37°C for 5 min and washed
with acetonitrile at 37°C for 10 min. Supernatants from washes
were pooled together with a trypsin digest supernatant. Pooled
sampleswere lyophilizedbyusinga speedvacuum.Each sample
was resuspended in 10 ml of 50 mM NH4HCO3 before LC-MS/
MS analysis. Peptideswere separated by reverse-phase LCusing
an EASY NanoLC system (Thermo Fisher Scientific) that was
equipped with a 75-mm3 15-cm reverse-phase C-18 column. A
3-step linear gradient of acetonitrile in 0.1% formic acid was ap-
plied (300 nl/min flow rate over 180 min) to separate peptides.
Eluent was ionized by electrospray ionization using an Orbitrap
Velos Pro (Thermo Fisher Scientific) operating with Xcalibur
software (v2.2; ThermoFisher Scientific). Peptideswereanalyzed
in positive ion mode. The instrument was programmed to ac-
quire in automated data-dependent switching mode, selecting
precursor ions on the basis of their intensity, for sequencing by
CID fragmentationusingaTop20CIDmethod.MS/MSanalyses
were conducted by using collision energy profiles that were
chosen on the basis of the mass-to-charge ratio (m/z) and the
charge state of the peptide.
Calpain activity assay
We measured calpain activity in vitro by using purified native
calpain I fromporcine erythrocytes (EMDMillipore, Billerica,MA,
USA) in buffer that contained calcium (50 mM Tris HCl, pH 7.8,
30 mM NaCl, 1 mM DTT, and 3 mM CaCl) or buffer without
calcium (50 mM Tris HCl, pH 7.8, 30 mMNaCl, 1 mMDTT, and
1 mM EGTA). All assays were in 100 ml total volume in a 96-well
formatandcarriedout in triplicate.Each reactioncontained1mgof
calpain I and 20mMof synthetic Suc-Leu-Leu-Val-Tyr-7-amino-4-
methylcoumarin fluorescent substrate (Calbiochem, San Diego,
CA, USA) in the appropriate buffer. Reactions were incubated for
10 min at 21°C before fluorescence readings were taken using the
GeminiXSplate reader (MolecularDevices, San Jose,CA,USA) for
1 h. Fluorophores were excited at 380 nM and the emission of the
cleaved substrate was measured at 460 nm.
Data analysis
Data arepresented asmeans6 SD. Comparisons between groups
were assessed for statistical significance by 1- or 2-way ANOVA
or ANOVA with repeated measures, where applicable. Where
significance was detected, individual mean values were com-
pared by using Bonferroni’s post hoc test. P values ,0.05 were
considered statistically significant.
RESULTS
Estimation of p38 isoform expression
in mouse heart
We first ascertained the relative level of expression of the 4
known p38 isoforms in WT mouse cardiac tissue. When
GST-tagged active human recombinant p38b, p38g, or
p38dMAPK (expectedMW, 62 kDa) were added to crude
heart homogenates and probed with Abs against each of
these isoforms, we observed monoselective binding (Fig.
1A).Data suggest that therewas little or no cross-reactivity
between isoform-specific Abs. In addition, we used
isoform-specific Abs against serially diluted (0.4–246 ng/
0.05 mg total protein/well) recombinant p38 MAPK pro-
teins to generate standard curves (data not shown) to de-
termine the relative expression of each isoform in the
murine heart (Fig. 1B). Our data suggest that the pre-
dominant isoforms that are expressed in the murine heart
are p38a and p38g, which is in agreement with the liter-
ature (17). Confocal analysis of isolated mouse cardiac
myocytes revealed that p38 MAPK—corresponding
mainly to the p38a MAPK isoform—is present in the cy-
toplasm and the nucleus (Fig. 1C). p38b MAPK is also
localized in the cytoplasm and displays a striated pattern
(Fig. 1D). p38g presents a punctuate distribution in the
cytoplasm of mouse cardiac myocytes (Fig. 1E) and, of
interest, p38d expression was observed at the intercalated
disks and the cytoplasm of cardiacmyocytes (Fig. 1F). The
selectivity of the signal was confirmed by using cardiac
myocytes from p38bKO and p38g/dKO hearts and a
negative control (no primary Ab).
Mice that lack the p38g isoform are protected
against pressure overload hypertrophy
We observed that homozygous KO mice from the p38gd-
targeted colony were resistant to cardiac hypertrophy
when subjected to supra-renal aortic constriction (band-
ing).WThearts responded to both stressors by exhibiting a
characteristic increase in heart mass (heart mass:body
weight and heart weight:tibia length), systolic diameter,
and end diastolic volume, as well as a decrease in ejection
fraction (Fig. 2A–E). This effectwas significantly blunted in
p38gdKOmice for all relevant parameters. On the basis of
the relative abundance of p38g vs. p38d (Fig. 1), we hy-
pothesized that this phenotype was the result of p38g de-
ficiencyalone.Afterbackcrossing,mice that lackedonly the
p38g isoform demonstrated a response that was similar to
those that lacked both p38g and p38d. Of note, ejection
fraction, fractional shortening, and endocardial fractional
area of change were preserved in p38gKO mice at 5 wk
after banding (Fig. 3A–C) and KO hearts exhibited signif-
icantly less LV chamber dilatation and myocardial wall
thickening compared with WT litter mates (Fig. 3D–F).
Consequently, hearts from p38gKO mice were signifi-
cantly smaller than those from WT mice (Fig. 4A), and
therewere fewer signs of pulmonary edema inKOmice as
measured by the postmortemwet:dryweight of the lungs
(Fig. 4B). Histochemical analysis of cryopreserved heart
tissue revealed that p38gKO hearts had less hypertrophic
growth as shownbymyocyte cross-sectional area (Fig. 4C)
and myocardial expression of the slow isoform of myosin
heavy chain (b-MHC) compared with WT littermates,
which suggests that remodeling was reduced with the
ablationofp38g (Fig. 4D).Wealsoobserved theexpression
of p38g in the nuclei of myocytes at 5 wk after banding
(Fig. 4E), which is consistent with previous data (17).
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Nucleotide specificity of AS p38g
To differentiate cardiac substrates of p38g from other ki-
nase substrates,we set out to identify anN6expandedATP
analog that could be utilized by AS p38g, but not by WT
p38g, for phospho transfer. To achieve this, in vitro kinase
assayswere set upusingATPand 4differentN6 expanded
ATP analogs [6-Bn-ATP, 6-PhEt-ATP, 6-Fu-ATP, and 6-(1-
MeBu)-ATP]. AS p38g could utilize all N6 expanded ATP
analogs tested tophosphorylateATF2. In comparison,WT
p38g could not utilize the N6 expanded ATP analogs
to phosphorylate ATF2 as efficiently, as a signal for
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Figure 1. Characterization of p38 isoform expression in the mouse heart. Estimation of p38 isoforms in the mammalian heart. A)
Whole-heart homogenates were spiked with GST-tagged recombinant proteins (240 ng/well) and probed with isoform-specific
mAbs and a total (pan-isoform) Ab. Arrows indicate the endogenously expressed p38a and p38g also detected in crude heart
homogenate. B) After serial dilution of recombinant protein, standard curves were generated for each specific isoform Ab, and
the relative endogenous expression of each isoform was determined. C–F) Expression and subcellular distribution of total Ab,
corresponding mainly to p38a (C), p38b (D), p38g (E), and p38d MAPK (F) isoforms in isolated mouse cardiac myocytes.
Negative control (C–E) contained no primary Ab. Data (B) are shown as means 6 SD (n = 5/group).
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phosphorylated ATF2 was only observed with longer ex-
posures (Fig. 5A, p-ATF2 probe, bottom). From this longer
exposure,WTp38g is less efficient at utilizing 6-PhEt-ATP
and 6-(1-MeBu)-ATP than 6-Bn-ATP and 6-Fu-ATP. 6-
PhEt-ATP was chosen for use in all subsequent experi-
ments to label direct substrates of p38g.
To specifically track and identify substrates of p38g
among the multitude of cardiac proteins, AS p38g
must be able to utilize 6-PhEt-ATPgS, which is further
modified at the g-phosphate to substitute a thiol group
to thiophosphorylate downstream substrates (Fig. 5C).
This was again assessed in vitro by using ATF2 as
substrate (Fig. 5B). To detect thiophosphorylation of
ATF2, kinase assays were subsequently alkylatedwith
PNBM. This generates thiophosphate esters that form
the epitope for recognition by the thiophosphate Ab.
Whereas AS p38g successfully thiophosphorylated
ATF2 by using 6-PhEt-ATPgS, we did not observe
thiophosphorylation of ATF2 with WT p38g or in the
nonalkylated AS p38g control sample.
Thiophosphorylation and identification of
cardiac substrates by AS p38g
To identify cardiac substrates of p38g, we incubated
AS p38g and 6-PhEt-ATPgS with WT murine heart
homogenate. Reactions were supplemented with
0.2 mM ATP and 3 mM GTP to reduce background
signal caused by use of 6-PhEt-ATPgS by endogenous
kinases (Supplemental Fig. 1). Upon termination of
assays, a small sample of each assay was removed,
alkylated with PNBM, and prepared for immunoblot
analysis to monitor the thiophosphorylation reaction
(Fig. 5D). Incubation of heart homogenate with
both AS p38g and 6-PhEt-ATPgS results in thio-
phosphorylation of many cardiac proteins. As thio-
phosphorylation was successfully determined, the
remaining samples were processed in triplicate to
enrich phosphopeptides and were analyzed by LC-
MS/MS to identify substrates of p38g. This identified
86 potential cardiac substrates of p38g (Supplemen-
tal Table 1). Among the 86 proteins identified, LDB3
and calpastatin were identified as novel putative
substrates of p38g. LDB3 was determined to un-
dergo phosphorylation at 2 potential sites (Ser98 and
Ser240), and calpastatin was determined to un-
dergo phosphorylation at 6 potential sites (Thr216,
Ser219, Ser459, Thr460, Ser466, and Thr467). Of interest,
both LDB3 sites and 3 calpastatin sites (Thr216, Ser219,
and Thr467) are adjacent to a +1 proline residue,
which forms the consensus motif for MAPK
phosphorylation.
Figure 2. Physiologic and morphologic parameters measured in mice from WT and p38g2/2d2/2 mice that were subjected to
abdominal aortic banding surgery (banding). A, B) Calculated LV mass-to-body mass ratio (A) and LV end systolic diameter (B) in
mice that were subjected to abdominal aortic banding assessed by serial cardiac ultrasound in WT (open bars) or p38g/d dual KO
(black bars) mice. C) Heart weight (HW) -to-tibia length (TL) ratio assessed postmortem at 5 wk after banding surgery. D, E) Percent
ejection fraction (D) and end diastolic volume (E) assessed by pressure–volume analysis at 5 wk after abdominal aortic banding. Data
are shown as means6 SD (n = 10–12/group). *P , 0.05, **P , 0.01 vs. control; #P , 0.05, ##P , 0.01 vs. corresponding WT control.
p38g MAPK CONTRIBUTES TO LEFT VENTRICULAR REMODELING 13137
Downloaded from www.fasebj.org by Kings College London Journals (193.61.203.144) on December 18, 2019. The FASEB Journal Vol. ${article.issue.getVolume()}, No. ${article.issue.getIssueNumber()}, pp. 13131-13144.
LDB3 and calpastatin are true substrates of
p38g in vitro
To validate LDB3 and calpastatin as true substrates of
p38g, we generated recombinant proteins for use in in
vitro kinase assays with p38g. To overcome the lack of
phospho-specific Abs, kinase assays were performed
with ATPgS and thiophosphorylation of proteins was
examined. WT p38g successfully thiophosphorylated
LDB3 (Fig. 6A) and calpastatin (Fig. 7A). Stoichiometry
of the phosphorylation of both substrates by WT p38g
using ATP was examined by Phostag SDS-PAGE gel
and silver stain analysis. Phostag SDS-PAGE is a vari-
ation of the traditional SDS-PAGE analysis whereby
the Phostag reagent captures phosphomonoester di-
anions that are bound to serine, threonine, or tyrosine
residues and results in a mobility shift of the phos-
phorylated proteins in SDS-PAGE (16). In both cases, in
contrast to control reactions, several higher MW bands
were encountered upon LDB3 and calpastatin phos-
phorylation by p38g (Figs. 6B and 7B, respectively).
This is in agreement with the LC-MS/MS analysis that
demonstrated that several sites are targeted for phos-
phorylation by p38g. As LDB3 contains a PDZ do-
main, we investigated whether phosphorylation was
PDZ interaction dependent by assessing LDB3 thio-
phosphorylation using WT and C-terminal truncated
p38g; however, both WT and C9-truncated p38g
phosphorylated LDB3 to the same extent at all the time
points measured.
As a positive control, we also examined the thio-
phosphorylation of a1-syntrophin, a known sub-
strate of p38g (5). As expected, WT p38g successfully
thiophosphorylated a1-syntrophin (Fig. 6E). TAB1 is a
substrate of p38a, and we have previously shown that
TAB1 interacts with p38a via 2 distinct sites—at the
upper canonical site used by other interacting partners
of p38a and a lower, noncanonical TAB1 unique bind-
ing site (16). As such, we investigated whether TAB1 is
also phosphorylated by p38g and included reactions
with TAB1 mutated at the sites involved in canonical
site interaction (CM). We found that, although p38a
enhances the phosphorylation of both WT and CM
TAB1, as expected, p38gwas not able to phosphorylate
TAB1 (Fig. 6D); therefore, TAB1 is not a substrate of
p38g.
We next sought to independently validate the p38g
phospho sites on calpastatin that were previously
identified by LC-MS/MS analysis of thiophosphory-
lated cardiac proteins. For this, we excised bands from
Phostag gels and performed LC-MS/MS analysis. This
second round of analysis confirmed that all proline-
directed sites that were initially detected (Ser98 and
Ser240 for LDB3; Thr216, Ser219, and Thr467 for calpas-
tatin) are phosphorylated by p38g. In addition, several
other sites were determined to undergo phosphory-
lation by p38g (Supplemental Tables 2 and 3). For
subsequent experiments, we focused solely on the
p38g-mediated phosphorylation of calpastatin.
Phosphorylation of Thr216, Ser219, and Thr467
calpastatin by p38g
Calpastatin contains 4 repetitive inhibitory domains (I–IV)
that can each reversibly inhibit 1 calpainmolecule (18, 19).
Figure 3. Ablation of p38g protects mouse hearts from pathologic hypertrophy. Physiologic and morphologic parameters assessed
by cardiac ultrasound in age- and sex-matched WT (open bars) and p38gKO (black bars) mice at 5 wk after abdominal aortic
banding (banded) or sham surgery. A) LV percent ejection fraction. B) LV fractional shortening. C) Endocardial fractional area
changes (FAC%). D) LV posterior wall thickness at systole. E) LV internal diameter at systole. F) LV internal diameter at diastole.
Data are shown as means 6 SD (n = 7–9/group). *P , 0.05 vs. control; #P , 0.05 and ##P , 0.01 vs. corresponding WT control.
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Examinationof thepeptide sequenceandcrystal structureof
calpastatin revealed that Thr216 and Ser219 are located before
the first inhibitory domain of calpastatin, and Thr467 is lo-
cated between inhibitory domains II and III. Therefore, we
engineered double T216A/S219A- and a single T467A
phosphorylation–deficient mutants of calpastatin. As be-
fore, purified mutants were subject to in vitro kinase assays
with p38g and ATP (Fig. 7C). Samples were then probed
with custom calpastatin phospho-Abs against these sites.
Both phospho-calpastatin Abs—pT216/S216 and pT467—
detected phosphorylation of WT calpastatin, but not of
the respective alanine mutants, which confirmed that
Thr216, Ser219, and Thr467 are phosphorylated by p38g
in vitro.
Phosphorylation of calpastatin reduces its
inhibitory efficiency
To determine what effect phosphorylation has on the
function of calpastatin, we next conducted in vitro fluoro-
metric calpain assays. The synthetic calpain substrate, 7-
amino-5-methylcoumarin, is cleaved by calpain, which
results in increased fluorescence only when calcium is
present in thebuffer (Fig. 8A). Theadditionof recombinant
WT calpastatin (0.2–4.5 mg) to the assay in its non-
phosphorylated form resulted in the dose-dependent in-
hibition of calpain activity, as a corresponding decrease in
fluorescence was observed (Fig. 8B). Lastly, a significant































































































Figure 4. Ablation of p38g
protects mouse hearts from
pathologic remodeling. Mor-
phologic and histologic analysis
of cardiac tissue fromWT (open
bars) and p38gKO (black bars)
mice at 5 wk after abdominal
aortic banding (banded) or sham
surgery. A) Calculated LV mass-
to-body mass ratio. B) Lung wet-
to-dry weight ratio was assessed
postmortem. C, D) Myocyte cross-
sectional area (C) and b-MHC
expression (D) were assessed by
confocal microscopy after cryo-
sectioning at a thickness of
30 mm and probing with the
appropriate agents [anti–b-
MHC Ab and fluorophore-con-
jugated wheat germ agglutinin
(WGA)] with computer-aided
analysis. For each measure, a
minimum of 5 images were
used for measurements, and a
minimum of 250 cells were
analyzed from each heart. E)
Subcellular localization of p38g
was determined by using spe-
cific Abs in sham and banded
(5 wk) hearts. Arrows indicate
localization of p38g immunore-
activity in nuclei of cardiac
myocytes. Data are shown as
means 6 SD (n = 7–9/group).
*P , 0.05 vs. control, #P , 0.05
vs. corresponding WT control.
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calpastatin between its nonphosphorylated and p38g-
phosphorylated form (Fig. 8C). Increased fluorescence
was observed with phospho-calpastatin, which indicated
that phosphorylation of calpastatin by p38g reduces the
inhibitory efficiency of calpastatin. This reduction of the
inhibitory effect of calpastatinwas reversedwhenweused
a double T216A/S219A phosphorylation–deficient mu-
tant of calpastatin (Fig. 8C)
DISCUSSION
The purpose of the current study was to decipher the role
played by p38g in the heart. To summarize our findings,
we have shown that p38g is expressed in the heart and is
an important regulator of the progression of cardiac hy-
pertrophy. By using the Shokat approach to identify sub-
strates of protein kinases, we have discovered LDB3 and
calpastatin, among other substrates, to be novel targets of
p38g. Both proteins are indispensable to cardiac myocyte
function. LDB3 is a key cytoskeletal protein in car-
diomyocytes, and calpastatin is the natural and endoge-
nous inhibitor of calpain proteases. Although we were
unable to assess the consequences of p38g-mediatedLDB3
phosphorylation, we observed that phosphorylation of
calpastatin by p38g reduces the efficiency of calpastatin in
inhibitingcalpain. If thisdisinhibitionoccurs in vivo, itmay
be an important mechanism by which p38g mediates its
prohypertrophic role in the heart.
Phenotype of p38gKO mice after cardiac stress
Data presented here confirm the prohypertrophic role of
p38g in the myocardium. Global p38gKO mice are less
susceptible to the effects of pressure overloadhypertrophy
compared with WT controls (Figs. 2 and 3), which is con-
sistent with the recent findings by the Sabio group (9).
The LV of WT mice gradually increased in mass and
contraction was impaired, as indicated by an increase in
internal diameter. Despite the roles for this isoform that
have been described in skeletal muscle development and
maintenance, blunted growth of p38gKO mice was not a
confounding factor in this study (20).
Immunohistochemistry of hearts revealed an increase
in the expression of b-MHC and an increase in myocyte
Figure 5. Immunoblot analysis of in vitro kinase assays of p38g kinases with ATF2 or WT heart homogenate as substrate. A)
Phosphorylation of ATF2 (1 mg) by WT and AS p38g kinases (200 ng) using ATP (1 mM) and various N6 expanded ATP analogs
(1 mM) after 30 min at 30°C. For the phospho-ATF2 signal, 2 different exposures of film are shown. B) Thiophosphorylation of
ATF2 by WT and AS p38g kinases using PhEt-ATP-g-S (1 mM). Samples were alkylated with PNBM (5 mM) for 1 h before
immunoblot analysis. C) Chemical structure of PhEt-ATP-g-S. D) Thiophosphorylation of cardiac proteins after spiking of WT
heart homogenate (2 mg) with recombinant AS p38g (20 mg) and 6-PhEt-ATPgS (1 mM) in triplicate. A 20-ml aliquot was
removed from each reaction and alkylated with PNBM (5 mM) for 1 h before immunoblot analysis. Remaining samples were
processed for LC-MS/MS.
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cross-sectional area, both of which are hallmarks of ex-
perimental cardiac hypertrophy (5, 21, 22), in bandedWT
but not KOhearts (Fig. 3), which supports the observation
that p38g is involved the progression of pathologic cardiac
hypertrophy.
Cardiac substrates of p38g
Two novel cardiac substrates of p38g identified in the cur-
rent study are LDB3 and calpastatin. Extensive character-
ization of these proteins and their p38g phosphorylation
sites has been carried out in vitro, and we have confirmed
thephosphorylationofbothproteinsbyp38g (Figs.6and7).
Phostag gel analysis, mass spectrometry, and custom
phospho-Abs against the phosphorylated protein sub-
strates demonstrate that both substrates are phosphory-
lated by p38g at multiple sites. LDB3 is phosphorylated by
p38g at Ser98 and Ser240, and calpastatin is phosphorylated
by p38g at Thr197/Ser200 and Thr448 (Fig. 7). All sites, to our
knowledge, are novel phosphorylation sites that have not
previously been described. Of interest, both substrates
identified here have previously been implicated in cardiac
hypertrophy, as discussed further below.
Figure 6. In vitro validation of LDB3 and a1-syntrophin, but not TAB1, as substrates of p38g. A) Immunoblot analysis of LDB3
(1 mg) thiophosphorylation by WT p38g (200 ng) using ATPgS (1 mM) after 30 min at 30°C. B) Phostag SDS-PAGE gel and silver
stain analysis of LDB3 phosphorylation by WT p38g with ATP (1 mM) after 30 min at 30°C (dotted line indicates where irrelevant
lanes have been removed for clarity). C) Immunoblot analysis of LDB3 (1 mg) thiophosphorylation by WT or C9 truncated p38g
(200 ng) using ATPgS after 1, 5, or 10 min. D) Immunoblot analysis of WT TAB1 or CM TAB1 phosphorylation by WT p38a and
p38g with ATP after 30 min at 30°C. E) Immunoblot analysis of a1-syntrophin (1 mg) thiophosphorylation by WT p38g using
ATPgS after 30 min at 30°C.
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LDB3
LDB3 is a key cytoskeletal scaffold protein in car-
diomyocytes (23). LDB3-null mice are not viable, and
cardiac-specific or inducible cardiac-specific LDB3 KO
mice display disrupted cardiomyocyte structure, de-
creased cardiac function, and eventually develop a severe
form of dilated cardiomyopathy, followed by premature
death (24). Furthermore, mutations in the ZASP gene
(human ortholog) have been associated with dilated car-
diomyopathies (25) and LV noncompaction (25, 26) in
humans, which demonstrates the essential role of LDB3 in
the heart.
Of interest, LDB3 contains a PDZ domain; however, the
interaction of the PDZ domain of LDB3 with the PDZ
domain-interacting motif of p38g was not necessary for
successful substrate phosphorylation, as C9 truncated p38g
could phosphorylate LDB3 to the same extent asWT p38g,
at least under in vitro experimental conditions tested here
(Fig. 6).
Calpastatin
Calpastatin is the natural and endogenous inhibitor
of calpain proteases. Calpain proteases are cysteine-
dependent proteases that are activated by increased
intracellular calcium in such scenarios as cardiac hy-
pertrophy and remodeling. Previous studies have
demonstrated that inhibition of calpain activity during
pathophysiologic circumstances demonstrates favorable
improvements in cardiac function (27–29). Results from
animal studies of calpain in cardiac remodeling are sup-
ported by data from patients with congestive heart
failure. A significant increase in calpain 1 and 2 protein
and a concomitant increase in the cleavage of calpain
substrate cain/cabin 1 has been reported in severe
failing hearts compared with hearts from healthy
controls (30).
In support of previous studies (31, 32), we have
clearly demonstrated that phospho modification of
calpastatin can modulate its ability to inhibit calpain.
We speculate that this may be a mechanism by which
p38g mediates its prohypertrophic role in the heart. A
crucial substrate of calpain is the serine/threonine-
specific phosphatase, calcineurin. Elevation in in-
tracellular calcium or cleavage of the autoinhibitory
domain of calcineurin by calpain can activate calci-
neurin (33). Once active, calcineurin dephosphorylates
nuclear factor of activated T cell (NFAT) transcription
factors, key prohypertrophic transcription factors in
the heart. Dephosphorylated NFAT transcription fac-
tors then translocate to the nucleus to increase tran-
scription of prohypertrophic genes. In principle, this
could place p38g within a well-established hypertro-
phic signaling cascade. p38g-mediated phosphoryla-
tion of calpastatin would result in unrestrained calpain
activity, increased calcineurin activation, and a con-
comitant increase in NFAT activity. Although other
targets of p38g may contribute to the development of
pathologic cardiac hypertrophy, this pathway may
explain, in part, the resistance of p38gKO mice to
Figure 7. In vitro validation of
calpastatin (CS) as a substrate of
p38g, and determination of CS
residues Thr216 and/or Ser219 and
Thr467 as targets of p38g. A) immu-
noblot analysis of CS (1 mg) thio-
phosphorylation by WT p38g
(200 ng) using ATPgS (1 mM) after
30 min at 30°C. B) Phostag SDS-
PAGE gel and silver stain analysis of
CS phosphorylation by WT p38g
with ATP (1 mM) after 30 min at
30°C (dotted line indicates where
irrelevant lanes have been removed
for clarity). C) Immunoblot analysis
of WT and phospho-mutant CS
phosphorylation by WT p38g with
ATP after 30 min at 30°C
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pressure overload hypertrophy compared with WT
mice and warrants additional investigation.
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